120 related articles for article (PubMed ID: 8639381)
1. New anticancer agents.
Weiss GR; Burris 3rd HA; Eckardt JR; Eckhardt SG; Fields SM; O'Rourke T; Rodriguez GI; Rothenberg ML; Valley AJ
Cancer Chemother Biol Response Modif; 1996; 16():132-67. PubMed ID: 8639381
[No Abstract] [Full Text] [Related]
2. Inhibition of angiogenesis in cancer patients.
Verheul HM; Pinedo HM
Expert Opin Emerg Drugs; 2005 May; 10(2):403-12. PubMed ID: 15934875
[TBL] [Abstract][Full Text] [Related]
3. New drugs target hypoxia response in tumors.
Garber K
J Natl Cancer Inst; 2005 Aug; 97(15):1112-4. PubMed ID: 16077066
[No Abstract] [Full Text] [Related]
4. Diflomotecan. Ipsen.
Osheroff N
IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
[No Abstract] [Full Text] [Related]
5. Receptor tyrosine kinase inhibitors as anti-angiogenic agents.
Kim DW; Lu B; Hallahan DE
Curr Opin Investig Drugs; 2004 Jun; 5(6):597-604. PubMed ID: 15242247
[TBL] [Abstract][Full Text] [Related]
6. Experimental chemotherapeutic agents for the treatment of colorectal carcinoma.
O'Reilly S; Rowinsky EK
Hematol Oncol Clin North Am; 1997 Aug; 11(4):721-58. PubMed ID: 9257153
[TBL] [Abstract][Full Text] [Related]
7. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma.
Belani CP
Semin Oncol; 2004 Dec; 31(6 Suppl 14):25-33. PubMed ID: 15726531
[TBL] [Abstract][Full Text] [Related]
8. Development of novel alkylating drugs as anticancer agents.
Izbicka E; Tolcher AW
Curr Opin Investig Drugs; 2004 Jun; 5(6):587-91. PubMed ID: 15242245
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
10. The resurgence of platinum-based cancer chemotherapy.
Kelland L
Nat Rev Cancer; 2007 Aug; 7(8):573-84. PubMed ID: 17625587
[TBL] [Abstract][Full Text] [Related]
11. [Can new therapy concepts in oncology still be realized? Earlier death with standard therapy].
Pickl S
MMW Fortschr Med; 2002 Dec; 144(49):14. PubMed ID: 12577732
[No Abstract] [Full Text] [Related]
12. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
13. New targets for non-small-cell lung cancer therapy.
Alvarez M; Roman E; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
[TBL] [Abstract][Full Text] [Related]
14. ZD-6126 AstraZeneca.
Soltau J; Drevs J
IDrugs; 2004 Apr; 7(4):380-7. PubMed ID: 15057644
[TBL] [Abstract][Full Text] [Related]
15. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.
Gradishar WJ
Invest New Drugs; 1997; 15(1):49-59. PubMed ID: 9195289
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial transparency: registries, databases raise questions, stir debate.
Benowitz S
J Natl Cancer Inst; 2005 Nov; 97(22):1640-1. PubMed ID: 16288115
[No Abstract] [Full Text] [Related]
17. Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer.
Clark JW
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-19-S18-24. PubMed ID: 9420017
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials in adult AML.
Stock W
Clin Adv Hematol Oncol; 2009 Jun; 7(6):8-10. PubMed ID: 19645130
[No Abstract] [Full Text] [Related]
19. New investigational drugs for lymphoma.
Younes A
Clin Adv Hematol Oncol; 2009 May; 7(5):308-10. PubMed ID: 19521318
[No Abstract] [Full Text] [Related]
20. New checkpoint blockers begin human trials.
Garber K
J Natl Cancer Inst; 2005 Jul; 97(14):1026-8. PubMed ID: 16030295
[No Abstract] [Full Text] [Related]
[Next] [New Search]
